Cargando…
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
BACKGROUND: Many countries are experiencing a resurgence of COVID-19, driven predominantly by the delta (B.1.617.2) variant of SARS-CoV-2. In response, these countries are considering the administration of a third dose of mRNA COVID-19 vaccine as a booster dose to address potential waning immunity o...
Autores principales: | Barda, Noam, Dagan, Noa, Cohen, Cyrille, Hernán, Miguel A, Lipsitch, Marc, Kohane, Isaac S, Reis, Ben Y, Balicer, Ran D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555967/ https://www.ncbi.nlm.nih.gov/pubmed/34756184 http://dx.doi.org/10.1016/S0140-6736(21)02249-2 |
Ejemplares similares
-
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Barda, Noam, et al.
Publicado: (2021) -
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021) -
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021) -
Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older
por: Auster, Oren, et al.
Publicado: (2022) -
Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
por: Dagan, Noa, et al.
Publicado: (2021)